Aim: We hypothesized that certain effects of the general anaesthetic thiopental are dependent on NO-related mechanisms, which were consequently counteracted by stable gastric pentadecapeptide BPC 157.

Main Methods: (1) All rats intraperitoneally received thiopental (20, 30, 40, and 50 mg/kg) while medication BPC 157 (10 μg/kg, 10 ng/kg, and 10 pg/kg) was given intraperitoneally at 5 min before thiopental. (2) To determine NO-related mechanisms, all rats received intraperitoneally thiopental 40 mg/kg while BPC 157 (10 μg/kg), L-NAME (10 mg/kg) and L-arginine (30 mg/kg) were applied alone and/or combined. BPC 157 was given at 25 min before thiopental while L-NAME, L-arginine, alone and/or combined, were applied at 20 min before thiopental.

Key Findings: (1) BPC 157 own effect on thiopental anaesthesia: BPC 157 (10 ng/kg and 10 μg/kg) caused a significant antagonism of general anaesthesia produced by thiopental with a parallel shift of the dose-response curve to the right. (2) L-NAME-L-arginine-BPC 157 interrelations: L-NAME: Thiopental-induced anaesthesia duration was tripled. L-arginine: Usual thiopental anaesthesia time was not influenced. Active only when given with L-NAME or BPC 157: potentiating effects of L-NAME were lessened, not abolished; shortening effect of BPC 157: abolished. BPC 157 and L-NAME: Potentiating effects of L-NAME were abolished. BPC 157 and L-NAME and L-arginine: BPC 157 +L-NAME +L-arginine rats exhibited values close to those in BPC 157 rats.

Significance: Thiopental general anaesthesia is simultaneously manipulated in both ways with NO system activity modulation, L-NAME (prolongation) and BPC 157 (shortening/counteraction) and L-arginine (interference with L-NAME and BPC 157).

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10787-015-0249-9DOI Listing

Publication Analysis

Top Keywords

bpc 157
56
bpc
15
0
14
thiopental
10
l-name
10
general anaesthetic
8
no-related mechanisms
8
thiopental mg/kg
8
157 μg/kg
8
min thiopental
8

Similar Publications

Article Synopsis
  • Moderate to severe interstitial cystitis (bladder pain syndrome) currently lacks effective long-term treatments, with pentosan polysulfate having limitations and potential side effects.
  • A study involving 12 women aged 39-76 tested BPC-157, an unapproved peptide, via bladder injections to evaluate its safety and efficacy for interstitial cystitis.
  • Results showed that 10 out of 12 patients experienced complete symptom resolution after one injection, while the remaining 2 reported significant improvement, marking the first positive report on BPC-157 for this condition.
View Article and Find Full Text PDF

Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?

Arthroscopy

September 2024

10th Medical Group, US Air Force Academy, San Antonio, Colorado, U.S.A.

High-level athletes and bodybuilders are constantly seeking novel therapies to enhance recovery and expedite return from injury-injectable peptides are a new and trending therapy that may be the wave of the future in the realm of regenerative medicine research in treating joint injuries and osteoarthritis. Very early in vivo research on pharmacokinetics indicates the possibility that body protection compound 157 (BPC-157) is at the forefront of therapeutic peptides, with early demonstrations of this experimental peptide optimizing endurance training, metabolism, recovery, and tissue repair. Although unregulated and yet readily available for purchase over the internet, there is scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides in tendon, muscle, and cartilage injury.

View Article and Find Full Text PDF

By introducing the healing of many distinctive anastomoses by BPC 157 therapy, this review practically deals with the concept of the resection and reconnection of the hollow parts of the gastrointestinal tract as one of the cornerstones of visceral surgery. In principle, the healing of quite distinctive anastomoses itself speaks for applied BPC 157 therapy, in particular, as a way in which the therapy of anastomoses can be successfully approached and carried out. Some of the anastomoses implicated were esophagogastric, colocolonic, jejunoileal, and ileoileal anastomoses, along with concomitant disturbances, such as esophagitis, sphincter dysfunction, failed intestinal adaptation, colitis, short bowel syndrome, major vessel occlusion, NO-system, and prostaglandins-system dysfunction, which were accordingly counteracted as well, and, finally, findings concerning other anastomoses healing (i.

View Article and Find Full Text PDF
Article Synopsis
  • * Clinical evidence supports BPC 157’s effectiveness in treating various conditions, including ulcerative colitis, with no side effects reported, and it demonstrates a capacity for tissue regeneration across multiple systems such as muscles, tendons, and the heart.
  • * The review discusses BPC 157's role in counteracting severe complications from major vessel failures and various organ system disturbances, emphasizing its use in conditions linked to alcohol-induced stomach lesions and overall vascular recovery.
View Article and Find Full Text PDF

We highlight the particular aspects of the stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity (not destroyed in human gastric juice, native and stable in human gastric juice, as a cytoprotection mediator holds a response specifically related to preventing or recovering damage as such) and its possible relations with neurotransmitter activity. We attempt to resolve the shortage of the pleiotropic beneficial effects of BPC 157, given the general standard neurotransmitter criteria, in classic terms. We substitute the lack of direct conclusive evidence (i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!